DOTA-GA(tBu)4

Overview

DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer .

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer | Products > Signaling Pathways > Radionuclide-Drug Conjugates (RDCs)

Product Information

• Catalog No.: HY-W614269
• CAS No.: 306776-79-4
• Molecular Formula: C35H64N4O10
• Molecular Weight: 700.90
• Purity: 98.69%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source